Announcements Trials

Browse Landscape

Phase

Status

Terminated 1 Completed 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Lymphoma, T-Cell 2 Hodgkin Disease 2 Mycosis Fungoides 1 Lymphoma, T-Cell, Peripheral 1 Lymphoma, T-Cell, Cutaneous 1 Lymphoma, Large-Cell, Anaplastic 1 Lymphoma, B-Cell 1 Lymphoma 1

Interventions

Cyclophosphamide 19 romidepsin 15 fludarabine phosphate 13 Whole-Body Irradiation 13 Peripheral Blood Stem Cell Transplantation 11 Mycophenolic Acid 11 Doxorubicin 11 Vincristine 10 Prednisone 10 Cyclosporine 10 10-propargyl-10-deazaaminopterin 10 Gemcitabine 8 Etoposide 8 Alemtuzumab 8 Bortezomib 6 Dexamethasone 5 Busulfan 5 Brentuximab Vedotin 5 mogamulizumab 4 denileukin diftitox 4 darinaparsin 4 Vitamin B 12 4 Nivolumab 4 Lenalidomide 4 Folic Acid 4 Carboplatin 4 carfilzomib 3 belinostat 3 Tacrolimus 3 Rituximab 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Lymphoma, T-Cell, Peripheral × AFM13 × Clear all

NCT04101331 2024-11-05

REDIRECT

Affimed GmbH

Phase 2 Completed

108 enrolled 24 charts

Lymphoma, T-Cell, Peripheral

Data powered by HemOnc (CC BY 4.0) Colophon ⚡